Tools
Tools
McClurg, Doreen, Elders, Andrew, Hagen, Suzanne, Mason, Helen, Booth, Jo, Cunnington, Anne-Louise, Walker, Richard, Deane, Katherine 
ORCID: https://orcid.org/0000-0002-0805-2708, Harari, Danielle, Panicker, Jalesh, Stratton, Susan, McArthur, Jaclyn, Sellers, Ceri and Collins, Marissa
(2022)
Stimulation of the tibial nerve—a randomised trial for urinary problems associated with Parkinson’s—the STARTUP trial.
Age and Ageing, 51 (6).
ISSN 0002-0729
Preview |
PDF (afac114)
- Published Version
Available under License Creative Commons Attribution. Download (623kB) | Preview |
Abstract
Background: non-motor symptoms such as bladder dysfunction are common (80%) in people with Parkinson’s increasing the risk for falls with a negative impact on health-related costs and quality of life. We undertook STARTUP to evaluate the clinical and cost-effectiveness of using an adhesive electrode to stimulate the transcutaneous tibial nerve stimulation (TTNS) to treat bladder dysfunction in people with Parkinson’s disease (PD). Study design, materials and methods: STARTUP was a parallel two-arm, multi-centre, pragmatic, double-blind, randomised controlled trial. Each participant attended one clinic visit to complete consent, be randomised using a computer-generated system and to be shown how to use the device. The trial had two co-primary outcome measures: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form and the International Prostate Symptom Score (IPSS). These were completed at baseline, 6 and 12 weeks. A bladder frequency chart and resource questionnaire were also completed. Results: two hundred forty two participants were randomised. About 59% of participants were male, the mean age was 69 years and mean time since diagnosis was 6 years. Questionnaire return rate was between 79 and 90%. There was a statistically significantly lower score in the active group at 6 weeks in the IPSS questionnaire (mean difference (Standard deviation, SD) 12.5 (6.5) vs 10.9 (5.5), effect size −1.49, 95% CI −2.72, −0.25). There was no statistically significant change in any other outcome. Conclusion: TTNS was demonstrated to be safe with a high level of compliance. There was a significant change in one of the co-primary outcome measures at the end of the treatment period (i.e. 6 weeks), which could indicate a benefit. Further fully powered RCTs are required to determine effective treatments.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | parkinson’s,bladder dysfunction,neurology,neuromodulation,older people,ageing,geriatrics and gerontology ,/dk/atira/pure/subjectarea/asjc/1300/1302 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > School of Health Sciences |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Dementia & Complexity in Later Life Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 22 Jun 2022 10:30 |
| Last Modified: | 19 Oct 2023 03:21 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/85744 |
| DOI: | 10.1093/ageing/afac114 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |